mGluR2 potentiator and cysreinyl leukotriene 1 antagonist, LY2300559, has proof of concept evidence for efficacy as migraine prevention in a randomised double-blind placebo-controlled trial (abstract only published) [159]. Here, GRM2 is linked to migraine disorder.